DARE
Daré Bioscience, Inc.NASDAQHealthcare$1.74+4.02%ClosedMarket Cap: $16.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
9.23
P/S
16.73
EV/EBITDA
1945.16
DCF Value
$197.23
FCF Yield
-59.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
-276.2%
Operating Margin
-1315.5%
Net Margin
-1300.7%
ROE
322.9%
ROA
-41.3%
ROIC
-0.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.0M | 5.7% | $-1.5M | $-1.4M | $-0.10 | — |
| FY 2025 | $1.03B | -0.1% | $-13.6M | $-13.4M | $-1.20 | — |
| Q3 2025 | $2.3K | -26993.9% | $-3.7M | $-3.6M | $-0.28 | — |
| Q2 2025 | $-21.2K | 100.0% | $-3.8M | $-4.0M | $-0.45 | — |
| Q1 2025 | $25.4K | -8935.2% | $-4.6M | $-4.4M | $-0.50 | — |
| Q4 2024 | $-63.6K | 22446.0% | $-5.4M | $-5.5M | $-0.65 | — |
| FY 2024 | $9.8K | -146110.2% | $-23.5M | $-4.1M | $-0.48 | — |
| Q3 2024 | $41.7K | 40.0% | $-4.7M | $-4.7M | $-0.55 | — |
| Q2 2024 | $22.4K | 100.0% | $-7.4M | $12.9M | $1.52 | — |
| Q1 2024 | $9.3K | -36034.1% | $-6.0M | $-6.8M | $-0.81 | — |
| Q4 2023 | $1.8M | -1092.7% | $-5.2M | $-5.1M | $-0.69 | — |
| FY 2023 | $2.8M | -670.6% | $-30.9M | $-30.2M | $-4.15 | — |